A microbial metabolite remodels the gut-liver axis following bariatric surgery (Cell Host & Microbe 2021, 29:1-17)

報告日期: 2021/03/30
報告時間: 15:10/16:00
報告學生: 張思敏
講評老師: 徐瑋萱
附件下載:

A microbial metabolite remodels the gut-liver axis following bariatric surgery

Snehal N. Chaudhari, James N. Luo, David A. Harris, Hassan Aliakbarian, Lina Yao, Donggi Paik,Renuka Subramaniam, Arijit A. Adhikari, Ashley H. Vernon, Ayse Kilic¸ , Scott T. Weiss, Jun R. Huh, Eric G. Sheu, and A. Sloan Devlin.

Cell Host & Microbe29, 408–424, March 10, 2021

Speaker: Szu-Min Chang (張思敏)                      Time:15:10~16:00, Mar 30, 2021

Commentator: Dr.Wei-Hsuan Hsu (徐瑋萱老師)    Place: Room 602

Abstract:

Type 2 diabetes is non-insulin dependent chronic disease around the world. Bariatric surgery is an effective treatment for type 2 diabetes. Among different kinds of bariatric surgery, sleeve gastrectomy (SG) is most common surgery type. The diabetes patients showed rapid remission after SG. But the mechanism how patients relieved so fast is still unclear. In authors’ previous studies shown a specific bile acid (BA), cholic acid-7-sulfate (CA7S), and glucagon-like peptide-1 (GLP-1), the major incretin in human body, are increased post-SG. First, the authors demonstrated that microbiome played an important role to induce CA7S production and GLP-1 secretion. The synthesis of CA7S occurred in mouse liver was mediated by BA sulfotransferase enzyme (SULT2A1). Next, they found microbial metabolite lithocholic acid (LCA) which increased in portal vein after SG induced SULT2A1 expression via vitamin D receptor (VDR). Despite LCA was increased in portal vein, the production of LCA was decreased in mouse cecum post-SG. The authors discovered lower LCA level caused increase BA transporter, Asbt and Ostα, expression. Last, the authors used SG cecal microbiota transplantation (CMT) to germ-free mice recreating the pathway. According to these findings, the data showed LCA-VDR-SULT-CA7S might be a possible pathway how diabetes patients relieved rapidly after SG.

References:

  1. Heshmati, K. et al. (2019). Comparison of early type 2 diabetes improvement after gastric bypass and sleeve gastrectomy: medication cessation at discharge predicts 1-year outcomes. Surg. Obes. Relat. Dis. 15, 2025–2032
  1. Chaudhari, S.N.et al. (2020). Bariatric surgery reveals a gut-restricted TGR5 agonist with anti-diabetic effects. Nat. Chem. Biol.